Furthermore, the downregulation of RNA m6A writer METTL3 and WTAP expression and consequent loss of c-MET m6A mRNA is the possible mechanism for chidamide to increase the crizotinib sensitivity of NSCLC cells actively expressing c-MET. The gene discussed is METTL3; the disease is non-small cell lung carcinoma.